Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.

<h4>Background</h4>Most liver transplant recipients receive calcineurin inhibitors (CNIs), especially tacrolimus and cyclosporine, as immunosuppressant agents to prevent rejection. A controversy exists as to whether the outcomes of hepatitis C virus (HCV)-infected liver transplant patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhenmin Liu, Yi Chen, Renchuan Tao, Jing Xv, Jianyuan Meng, Xiangzhi Yong
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0107057
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849254248723775488
author Zhenmin Liu
Yi Chen
Renchuan Tao
Jing Xv
Jianyuan Meng
Xiangzhi Yong
author_facet Zhenmin Liu
Yi Chen
Renchuan Tao
Jing Xv
Jianyuan Meng
Xiangzhi Yong
author_sort Zhenmin Liu
collection DOAJ
description <h4>Background</h4>Most liver transplant recipients receive calcineurin inhibitors (CNIs), especially tacrolimus and cyclosporine, as immunosuppressant agents to prevent rejection. A controversy exists as to whether the outcomes of hepatitis C virus (HCV)-infected liver transplant patients differ based on the CNIs used. This meta-analysis compares the clinical outcomes of tacrolimus-based and cyclosporine-based immunosuppression, especially cases of HCV recurrence in liver transplant patients with end-stage liver disease caused by HCV infection.<h4>Methods</h4>Related articles were identified from the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Medline, and Embase. Meta-analyses were performed for the results of homogeneous studies.<h4>Results</h4>Nine randomized or quasi-randomized controlled trials were included. The total effect size of mortality (RR = 0.98, 95% CI: 0.77-1.25, P = 0.87) and graft loss (RR = 1.05, 95% CI: 0.83-1.33, P = 0.67) showed no significant difference between the two groups irrespective of duration of immunosuppressant therapy after liver transplantation. In addition, the HCV recurrence-induced mortality (RR = 1.11, 95% CI: 0.66-1.89, P = 0.69), graft loss (RR = 1.62, 95% CI: 0.64-4.07, P = 0.31) and retransplantation (RR = 1.40, 95% CI: 0.48-4.09, P = 0.54), as well as available biopsies, confirmed that histological HCV recurrences (RR =  0.92, 95% CI: 0.71-1.19, P = 0.51) were similar.<h4>Conclusion</h4>These results suggested no difference in posttransplant HCV recurrence-induced mortality, graft loss and retransplantation, as well as histological HCV recurrence in patients treated with tacrolimus-based and cyclosporine-based immunosuppresion.
format Article
id doaj-art-73dc7f5020b044b8ae3ae2b0afa29d13
institution Kabale University
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-73dc7f5020b044b8ae3ae2b0afa29d132025-08-20T03:56:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10705710.1371/journal.pone.0107057Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.Zhenmin LiuYi ChenRenchuan TaoJing XvJianyuan MengXiangzhi Yong<h4>Background</h4>Most liver transplant recipients receive calcineurin inhibitors (CNIs), especially tacrolimus and cyclosporine, as immunosuppressant agents to prevent rejection. A controversy exists as to whether the outcomes of hepatitis C virus (HCV)-infected liver transplant patients differ based on the CNIs used. This meta-analysis compares the clinical outcomes of tacrolimus-based and cyclosporine-based immunosuppression, especially cases of HCV recurrence in liver transplant patients with end-stage liver disease caused by HCV infection.<h4>Methods</h4>Related articles were identified from the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Medline, and Embase. Meta-analyses were performed for the results of homogeneous studies.<h4>Results</h4>Nine randomized or quasi-randomized controlled trials were included. The total effect size of mortality (RR = 0.98, 95% CI: 0.77-1.25, P = 0.87) and graft loss (RR = 1.05, 95% CI: 0.83-1.33, P = 0.67) showed no significant difference between the two groups irrespective of duration of immunosuppressant therapy after liver transplantation. In addition, the HCV recurrence-induced mortality (RR = 1.11, 95% CI: 0.66-1.89, P = 0.69), graft loss (RR = 1.62, 95% CI: 0.64-4.07, P = 0.31) and retransplantation (RR = 1.40, 95% CI: 0.48-4.09, P = 0.54), as well as available biopsies, confirmed that histological HCV recurrences (RR =  0.92, 95% CI: 0.71-1.19, P = 0.51) were similar.<h4>Conclusion</h4>These results suggested no difference in posttransplant HCV recurrence-induced mortality, graft loss and retransplantation, as well as histological HCV recurrence in patients treated with tacrolimus-based and cyclosporine-based immunosuppresion.https://doi.org/10.1371/journal.pone.0107057
spellingShingle Zhenmin Liu
Yi Chen
Renchuan Tao
Jing Xv
Jianyuan Meng
Xiangzhi Yong
Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
PLoS ONE
title Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
title_full Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
title_fullStr Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
title_full_unstemmed Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
title_short Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review.
title_sort tacrolimus based versus cyclosporine based immunosuppression in hepatitis c virus infected patients after liver transplantation a meta analysis and systematic review
url https://doi.org/10.1371/journal.pone.0107057
work_keys_str_mv AT zhenminliu tacrolimusbasedversuscyclosporinebasedimmunosuppressioninhepatitiscvirusinfectedpatientsafterlivertransplantationametaanalysisandsystematicreview
AT yichen tacrolimusbasedversuscyclosporinebasedimmunosuppressioninhepatitiscvirusinfectedpatientsafterlivertransplantationametaanalysisandsystematicreview
AT renchuantao tacrolimusbasedversuscyclosporinebasedimmunosuppressioninhepatitiscvirusinfectedpatientsafterlivertransplantationametaanalysisandsystematicreview
AT jingxv tacrolimusbasedversuscyclosporinebasedimmunosuppressioninhepatitiscvirusinfectedpatientsafterlivertransplantationametaanalysisandsystematicreview
AT jianyuanmeng tacrolimusbasedversuscyclosporinebasedimmunosuppressioninhepatitiscvirusinfectedpatientsafterlivertransplantationametaanalysisandsystematicreview
AT xiangzhiyong tacrolimusbasedversuscyclosporinebasedimmunosuppressioninhepatitiscvirusinfectedpatientsafterlivertransplantationametaanalysisandsystematicreview